Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Verapamil in effort angina: a multi-centre study].

M Vincenzi, E Braito, F Cappelletti

    Giornale Italiano Di Cardiologia
    |January 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Long-Range Transverse-Momentum Correlations and Radial Flow in Pb-Pb Collisions at the LHC.

    Physical review letters·2026
    Same author

    Search for Quasiparticle Scattering in the Quark-Gluon Plasma with Jet Splittings in pp and Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.

    Physical review letters·2025
    Same author

    First Measurement of A=4 Hypernuclei and Antihypernuclei at the LHC.

    Physical review letters·2025
    Same author

    Probing Strangeness Hadronization with Event-by-Event Production of Multistrange Hadrons.

    Physical review letters·2025
    Same author

    Measurements of Chemical Potentials in Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.

    Physical review letters·2024
    Same author

    Observation of Medium-Induced Yield Enhancement and Acoplanarity Broadening of Low-p_{T} Jets from Measurements in pp and Central Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.

    Physical review letters·2024
    Same journal

    [Proceedings of the National Cardiology Conference on Cardiac Emergencies: Prospect for the year 2000. Rome, Italy, 15-16 October 1999].

    Giornale italiano di cardiologia·2001
    Same journal

    [Heart rupture in acute myocardial infarction: advantages of the use of Doppler color echocardiography M-2D in coronary intensive care unit].

    Giornale italiano di cardiologia·2000
    Same journal

    [Risk identification and strategy for the prevention of sudden cardiac death after myocardial infarction].

    Giornale italiano di cardiologia·2000
    Same journal

    [Arrhythmic complications in patients with heart decompensation: when and how to treat].

    Giornale italiano di cardiologia·2000
    Same journal

    [Suboptimal exercise test in chronic heart decompensation: the six-minute walking test].

    Giornale italiano di cardiologia·2000
    Same journal

    [Orthostatic tachycardia syndrome. Update on etiology, diagnosis and treatment].

    Giornale italiano di cardiologia·2000
    See all related articles

    Verapamil effectively treats stable effort angina by reducing chest pain and nitroglycerin use. Higher Verapamil doses (360 mg/day) offer superior symptom relief and improved exercise tolerance compared to lower doses (240 mg/day).

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Stable effort angina is a common condition characterized by chest pain during physical exertion.
    • Current treatments aim to reduce myocardial oxygen demand and improve exercise tolerance.

    Purpose of the Study:

    • To evaluate the efficacy of Verapamil in treating stable effort angina.
    • To compare the effects of two different Verapamil dosages (240 mg/day and 360 mg/day).

    Main Methods:

    • A multi-center, double-blind, randomized, cross-over study involving 47 outpatients.
    • Patients received placebo, Verapamil 240 mg/day, and Verapamil 360 mg/day for one month each.
    • Evaluated outcomes included angina symptoms, nitroglycerin consumption, ECG, exercise tolerance, and recovery heart rate.

    Main Results:

    Related Experiment Videos

    • Verapamil significantly reduced angina attacks and nitroglycerin use, improving patient symptomatology.
    • Exercise performance improved, with no change in maximal rate-pressure product, but reduced double product at rest and during recovery.
    • The 360 mg/day dose showed greater improvements in angina frequency, symptoms, resting double product, and recovery rate than the 240 mg/day dose.

    Conclusions:

    • Verapamil demonstrates significant anti-anginal efficacy in patients with stable effort angina.
    • The drug reduces myocardial oxygen demand and enhances exercise tolerance.
    • A higher Verapamil dosage (360 mg/day) provides superior clinical benefits compared to a lower dosage (240 mg/day).